Genitourinary Cancers

David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).

Lana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma.

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the role of nivolumab in the treatment of patients with bladder cancer.

The FDA has granted a priority review to a supplemental new drug application for the use of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses a mature data set regarding nivolumab and ipilimumab in the treatment of patients with renal cell carcinoma.

Anobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma.

As a result of the most recent presidential election, it is a big unknown what the new administration will bring as it relates to the future of healthcare in the US.

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses the recent explosion of immunotherapy research in the treatment landscape of bladder cancer.

The tail-end of this year saw 2 annual conferences occurring at the same time: the 2016 Large Urology Group Practice Association annual meeting in Chicago, and the 15th annual International Kidney Cancer Symposium in Miami. Both are covered in this issue’s Conference Highlights section, featuring key stories and landmark research in their respective fields.

Even with 1 FDA approval of an immunotherapeutic agent in urothelial carcinoma—and more expected in the coming months—chemotherapy regimens will continue to play a pivotal part in the treatment of patients with this disease.

Three recent drug approvals have shifted the landscape in the second-line setting for renal cell carcinoma, and researchers are now setting their sights on transforming upfront care.

Immunotherapy may be having a moment in the changing landscape of bladder cancer, but expert Gopa Iyer, MD, advises that there is much research to be done before physicians replace chemotherapy with these agents upfront.

The FDA has granted a priority review to a biologics license application for the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Robert G. Uzzo, MD, discusses the promise of immunotherapies as well as the challenges with using them across different indications in renal cell carcinoma.

Daniel P. Petrylak, MD, sheds light on the emerging roles of both immunotherapy and targeted agents in the treatment of patients with bladder cancer.

Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.

Chung-Han (Joe) Lee, MD, medical oncologist Memorial Sloan Kettering Cancer Center, discusses sequencing therapies for patients with renal cell carcinoma (RCC).

Sanofi Pasteur plans to discontinue production of Bacillus Calmette-Guérin for the US market by mid-2017, startling physicians and patients who fear that a shortage of the widely used bladder cancer therapy will develop.

Immunotherapy combinations have significant potential as treatment for patients with renal cell carcinoma.

The treatment landscape of renal cell carcinoma is changing at a remarkably fast pace.

Gopa Iyer, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy options for patients with bladder cancer, but mentions how other agents are evolving the landscape. Iyer shared this insight during the 2016 OncLive® State of the Science Summit on Genitourinary Cancers.

Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Vitaly Margulis, MD, assistant professor of Urologic Oncology, UT Southwestern Medical Center, discusses 2 different approaches to administering adjuvant therapy for patients with renal cell carcinoma.

In the past decade, the addition of tyrosine kinase inhibitors has had a huge impact on the treatment of renal cell carcinoma in the first- and second-line settings. Currently available agents include sorafenib, sunitinib, pazopanib, axitinib, and the recently-added cabozantinib, and lenvatinib.

If any doubts remained that oncology practices were not going to be specific targets in the hacking of medical data, a breach at Central Ohio Urology Group has set the record straight.